Dimopoulos MA - Search Results

1

Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma.

Liapis K, Kastritis E, Bagratouni T, Vassiliou S, Papachristidis A, Charitaki E, Alevizopoulos N, Harhalakis N, Terpos E, Delimpasi S, Dimopoulos MA. Liapis K, et al. Among authors: dimopoulos ma. J BUON. 2015 Sep-Oct;20(5):1314-21. J BUON. 2015. PMID: 26537080 Free article.

2

Bortezomib in multiple myeloma.

Terpos E, Roussou M, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Expert Opin Drug Metab Toxicol. 2008 May;4(5):639-54. doi: 10.1517/17425255.4.5.639. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484921 Review.

3

Thalidomide in the treatment of multiple myeloma.

Kastritis E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Best Pract Res Clin Haematol. 2007 Dec;20(4):681-99. doi: 10.1016/j.beha.2007.09.001. Best Pract Res Clin Haematol. 2007. PMID: 18070713 Review.

4

Hematology: first-line bortezomib benefits patients with multiple myeloma.

Dimopoulos MA, Terpos E. Dimopoulos MA, et al. Nat Rev Clin Oncol. 2009 Dec;6(12):683-5. doi: 10.1038/nrclinonc.2009.171. Nat Rev Clin Oncol. 2009. PMID: 19942924

5

Zoledronic acid for all patients with newly diagnosed multiple myeloma?

Terpos E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Lancet Oncol. 2011 Aug;12(8):711-2. doi: 10.1016/S1470-2045(11)70178-4. Epub 2011 Jul 21. Lancet Oncol. 2011. PMID: 21771569 No abstract available.

6

Current treatments for renal failure due to multiple myeloma.

Kastritis E, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Expert Opin Pharmacother. 2013 Aug;14(11):1477-95. doi: 10.1517/14656566.2013.803068. Epub 2013 May 25. Expert Opin Pharmacother. 2013. PMID: 23705905 Review.

7

How I treat relapsed multiple myeloma.

Kastritis E, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2022 May 12;139(19):2904-2917. doi: 10.1182/blood.2020008734. Blood. 2022. PMID: 35007326 Free article.

8

Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.

Cohen YC, Joffe E, Benyamini N, Dimopoulos MA, Terpos E, Trestman S, Held-Kuznetsov V, Avivi I, Kastritis E. Cohen YC, et al. Among authors: dimopoulos ma. Leuk Lymphoma. 2016;57(6):1382-8. doi: 10.3109/10428194.2015.1121258. Epub 2016 Jan 4. Leuk Lymphoma. 2016. PMID: 26727104

9

Current treatment options for myeloma.

Terpos E, Rahemtulla A, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Expert Opin Pharmacother. 2005 Jun;6(7):1127-42. doi: 10.1517/14656566.6.7.1127. Expert Opin Pharmacother. 2005. PMID: 15957967 Review.

10

Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?

Dimopoulos MA, Kastritis E. Dimopoulos MA, et al. Leuk Lymphoma. 2006 Nov;47(11):2271-2. doi: 10.1080/10428190600908620. Leuk Lymphoma. 2006. PMID: 17107895 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,280 results

Search Page